Directory
>
Andrew Adams
Andrew Adams
Group Vice President - Molecule Discovery & Director, Lilly Institutes of Genetic Medicine | Eli Lilly and Company
Indianapolis, Indiana, United States
Andrew Adams
Summary
Andrew Adams is a seasoned professional in the field of biotechnology and pharmaceuticals, currently serving as the Group Vice President - Molecule Discovery at Eli Lilly. With a robust academic background in Zoology and Neuroscience from the University of Aberdeen, Andrew has dedicated his career to advancing drug discovery and development in areas such as cancer and diabetes research. His extensive experience spans various leadership roles within Eli Lilly, where he has significantly contributed to the company's genetic medicine initiatives. Andrew's work is characterized by a strong focus on translational research, bridging the gap between laboratory discoveries and clinical applications. He is also known for his innovative approach to problem-solving and his ability to lead cross-functional teams in high-stakes environments. Outside of his professional endeavors, Andrew is passionate about mentoring the next generation of scientists and fostering diversity in the STEM fields.
Andrew Adams
Work Experience
Group Vice President - Molecule Discovery & Director, Lilly Institutes of Genetic Medicine at
Eli Lilly and Company
June 2024 - Present
SVP Neuroscience Research & Director, Lilly Institute of Genetic Medicine at
Eli Lilly and Company
November 2023 - June 2024
Co-director, Lilly Institute for Genetic Medicine at
Eli Lilly and Company
January 2022 - December 2023
Senior Vice President, Neurodegeneration Research & Genetic Medicine at
Eli Lilly and Company
October 2022 - December 2023
Vice President, Lilly Genetic Medicine at Eli Lilly and Company at
Eli Lilly and Company
May 2020 - October 2022
Vice President, Neurodegeneration Research at
Eli Lilly and Company
January 2022 - October 2022
Chief Scientific Officer, RNA Therapeutics at
Eli Lilly and Company
February 2019 - May 2020
Senior Director, Head of External Innovation, Diabetes & Complications at
Eli Lilly and Company
February 2018 - June 2019
Director - Diabetes Innovation at
Eli Lilly and Company
May 2017 - February 2018
Research Advisor at
Eli Lilly and Company
November 2015 - May 2017
Group Leader - Adipose Biology & Energy Metabolism at
Eli Lilly and Company
November 2015 - May 2017
Senior Research Scientist at
Eli Lilly and Company
September 2014 - November 2015
Research Scientist at
Eli Lilly and Company
July 2012 - September 2014
Post Doctoral Research Fellow at
Eli Lilly and Company
June 2011 - July 2012
Post Doctoral Research Fellow at
Harvard University
March 2007 - June 2011
Andrew Adams
Education
January 2003 - January 2007
University of Aberdeen, B.Sc. Honours
January 2003 - January 2007
Frequently Asked Questions about Andrew Adams
What is Andrew Adams email address?
Andrew Adams's primary email address is ************@lilly.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Andrew Adams work for?
Andrew Adams is a Group Vice President - Molecule Discovery & Director, Lilly Institutes of Genetic Medicine at Eli Lilly and Company, a company specializing in Biological products, except diagnostic.
Where Andrew Adams graduated from?
Andrew Adams holds a degree in Zoology, Neuroscience from University of Aberdeen.
How can I directly contact Andrew Adams?
To contact Andrew Adams directly, you can use the email address ************@lilly.com. Complete contact information is available upon registration with Muraena.
Who is Andrew Adams?
Andrew Adams is a seasoned professional in the field of biotechnology and pharmaceuticals, currently serving as the Group Vice President - Molecule Discovery at Eli Lilly. With a robust academic background in Zoology and Neuroscience from the University of Aberdeen, Andrew has dedicated his career to advancing drug discovery and development in areas such as cancer and diabetes research. His extensive experience spans various leadership roles within Eli Lilly, where he has significantly contributed to the company's genetic medicine initiatives. Andrew's work is characterized by a strong focus on translational research, bridging the gap between laboratory discoveries and clinical applications. He is also known for his innovative approach to problem-solving and his ability to lead cross-functional teams in high-stakes environments. Outside of his professional endeavors, Andrew is passionate about mentoring the next generation of scientists and fostering diversity in the STEM fields.
Andrew`s contact details
************@lilly.com
*******@bidmc.harvard.edu
Colleagues
Executive Director
Senior Vice President, Pricing and Market Access - International
Executive Director - Congress Strategy, Planning & Execution Neuroscience Business Unit
Associate Vice President, Oncology Clinical Trial Acceleration
Associate Vice President- Lilly Research Laboratories Development Capabilities
Associate Vice President Discovery PKPD
Executive Director - Quality Assurance - RegCoR Program Lead
Associate Vice President
Executive Director - Global Orchestration
Executive Director-Immunology Translational Sciences